Caribou Biosciences (CRBU) Stock: $28 Price Target From H.C. Wainwright

By Amit Chowdhry ● Nov 30, 2021
  • The shares of Caribou Biosciences Inc (NASDAQ: CRBU) have received a $28 price target from H.C. Wainwright. These are the details.

The shares of Caribou Biosciences Inc (NASDAQ: CRBU) have received a $28 price target from H.C. Wainwright. And H.C. Wainwright analyst Robert Burns initiated coverage of Caribou Biosciences with a “Buy” rating and $28 price target.

Burns noted that the company is advancing an allogeneic and armored cellular therapy portfolio. And Burns pointed out that allogeneic cell therapy should significantly broaden the addressable population and drive the adoption of CAR-T therapeutic approaches in earlier-line treatment.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.